Linkenheim, Germany

Roger Molinet




Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2001-2010

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Roger Molinet: Innovator in Medical Radionuclides

Introduction

Roger Molinet is a notable inventor based in Linkenheim, Germany. He has made significant contributions to the field of medical radionuclides, holding a total of 3 patents. His work focuses on the development of methods and applications for radionuclides that are particularly beneficial in medical treatments.

Latest Patents

Molinet's latest patents include innovative methods for using Th-226 and its mother radionuclides in medicine. These radionuclides are designed for therapeutic, diagnostic, prophylactic, and pain palliation purposes, making them highly versatile in medical applications. Additionally, he has developed methods for preparing Bi-213 for human therapeutic use, which involves a detailed process of preparing and purifying the radionuclide for integration into radioimmunoconjugates.

Career Highlights

Throughout his career, Roger Molinet has worked with prominent organizations, including the European Community and the European Commission. His expertise in radionuclide applications has positioned him as a key figure in the medical innovation landscape.

Collaborations

Molinet has collaborated with notable professionals in his field, including Christos Apostolidis and Willem Janssens. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Roger Molinet's contributions to the field of medical radionuclides demonstrate his commitment to innovation and improving therapeutic methods. His patents reflect a deep understanding of the complexities involved in medical applications, paving the way for future advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…